替吉奥用于非小细胞肺癌治疗的研究及展望

被引：26

作者：

汪进良

焦顺昌

机构：

[1] 解放军总医院肿瘤内科

来源：

中华医学杂志 | 2010年 / 36期

关键词：

D O I：

暂无

中图分类号：

R686 [筋腱、韧带、滑囊疾病及损伤];

学科分类号：

100220 [骨科学];

摘要：

<正> 肺癌是当前肿瘤死亡的首要病因,其中非小细胞肺癌(NSCLC)约占肺癌总数的80%。大多数NSCLC在确诊时已是中晚期,因此治疗以全身化疗为主。目前公认的一线化疗方案仍以顺铂或卡铂为基础,但总体疗效欠佳。二线治疗有多西紫杉醇或培美曲塞或口服靶向药物治疗,但几乎所有患者经过多线治疗后都会出现药物抵抗,此时药物选择困难。因而,人们一直尝试将更多的其他抗肿瘤药物用于NSCLC

引用

共 8 条

[1]

Phase I Study of Oral S-1 Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer.[J].Kyoichi Kaira;Noriaki Sunaga;Noriko Yanagitani;Tadayoshi Kawata;Mitsuyoshi Utsugi;Kimihiro Shimizu;Takeshi Ebara;Hidemasa Kawamura;Tetsuo Nonaka;Hitoshi Ishikawa;Hideyuki Sakurai;Tatsuo Suga;Kenichiro Hara;Takeshi Hisada;Tamotsu Ishizuka;Takashi Nakano;Masatomo Mori.International Journal of Radiation Oncology; Biology; Physics.2009, 1

[2]

A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer [J].

Totani, Yoshitaka ;

Saito, Yuji ;

Hayashi, Masamichi ;

Tada, Toshihiko ;

Kohashi, Yasuo ;

Mieno, Yuki ;

Kato, Atsushi ;

Imizu, Hiromi ;

Yoneda, Yukiko ;

Hoshino, Tami ;

Uchiyama, Yasuhiro ;

Takeuchi, Yasuo ;

Okazawa, Mitsushi ;

Sakakibara, Hiroki .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) :1181-1185

[3]

A Phase I Study of TS-1 Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer [J].

Ohba, T. ;

Yamasaki, T. ;

Endo, Y. ;

Furuie, M. ;

Ohtani, Y. ;

Inase, N. ;

Yoshizawa, Y. .

JOURNAL OF CHEMOTHERAPY, 2009, 21 (01) :80-85

[4]

Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer [J].

Ishimoto, Osamu ;

Ishida, Takashi ;

Honda, Yoshihiro ;

Munakata, Mitsuru ;

Sugawara, Shunichi .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) :43-47

[5]

Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer [J].

Kaira, Kyoichi ;

Sunaga, Noriaki ;

Yanagitani, Noriko ;

Aoki, Haruka ;

Kawata, Tadayoshi ;

Utsugi, Mitsuyoshi ;

Shimizu, Yasuo ;

Shimizu, Kimihiro ;

Hisada, Takeshi ;

Ishizuka, Tamotsu ;

Mori, Masatomo .

ANTI-CANCER DRUGS, 2008, 19 (03) :289-294

[6]

Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug [J].

Urata, Yoshiko ;

Negoro, Shunichi ;

Satouchi, Miyako ;

Kurata, Takayasu ;

Yoshimura, Sho ;

Shimada, Temiko ;

Takada, Yoshiki .

MEDICAL ONCOLOGY, 2007, 24 (01) :103-107

[7]

A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer [J].

Kaira, Kyoichi ;

Sunaga, Noriaki ;

Yanagitani, Noriko ;

Imai, Hisao ;

Utsugi, Mitsuyoshi ;

Shimizu, Yasuo ;

Iijima, Hironobu ;

Tomizawa, Yoshio ;

Hisada, Takeshi ;

Ishizuka, Tamotsu ;

Saito, Ryusei ;

Mori, Masatomo .

ANTI-CANCER DRUGS, 2007, 18 (04) :471-476

[8]

The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines; UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic Potential.[J].Paulo M. Hoff.Investigational New Drugs.2000, 4

← 1 →